Brokerages Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Target Price at $39.50

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has been given an average recommendation of “Moderate Buy” by the thirteen research firms that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $39.50.

A number of equities research analysts recently commented on the company. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and upped their price objective for the company from $32.00 to $43.00 in a report on Wednesday, July 22nd. Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. Guggenheim boosted their target price on Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Truist Financial began coverage on Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price target for the company. Finally, New Street Research set a $43.00 price target on shares of Genmab A/S in a research report on Wednesday, July 22nd.

Institutional Investors Weigh In On Genmab A/S

Hedge funds have recently bought and sold shares of the company. Personal CFO Solutions LLC lifted its stake in shares of Genmab A/S by 3.7% during the 1st quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock worth $292,000 after buying an additional 386 shares during the last quarter. Parallel Advisors LLC grew its stake in Genmab A/S by 11.3% in the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after buying an additional 419 shares during the last quarter. CWM LLC grew its stake in Genmab A/S by 18.8% in the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after buying an additional 433 shares during the last quarter. Osaic Holdings Inc. raised its holdings in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the period. Finally, Orion Porfolio Solutions LLC raised its holdings in Genmab A/S by 2.3% in the 3rd quarter. Orion Porfolio Solutions LLC now owns 19,693 shares of the company’s stock valued at $604,000 after acquiring an additional 441 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Trading Up 0.7%

GMAB opened at $32.47 on Friday. The firm has a 50 day simple moving average of $31.00 and a 200 day simple moving average of $28.27. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $35.43. The company has a market cap of $20.25 billion, a price-to-earnings ratio of 25.57, a price-to-earnings-growth ratio of 1.81 and a beta of 0.84. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. On average, sell-side analysts anticipate that Genmab A/S will post 1.17 earnings per share for the current year.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.